Skip to Main Content

National Coverage Analysis (NCA) Tracking Sheet for Autologous Stem Cell Transplantation for AL Amyloidosis (CAG-00050N)

Autologous stem cell transplantation (ASCT) is a process in which stem cells are harvested from a patient’s bone marrow or peripheral blood, stored, and then transplanted back into the patient following high dose chemotherapy use to treat various malignancies. The Coverage Issues Manuel (CIM), §35-30 does not have a policy decision in regards to coverage of ASCT for AL amyloidosis. Thus, coverage NCDs are made at contractor’s discretion. HCFA must evaluate whether there is enough scientific evidence that supports the “reasonable” and “necessary” criteria for a national coverage decision.

Inpatient Hospital Services
Physicians' Services
Requestor Name(s)Daniel Wright, M.D., Boston Medical Center
Formal Request Accepted and Review Initiated09/17/1999
Expected NCA Completion Date12/17/1999
Public Comment Period10/18/1999 - 11/18/1999
Decision Memo Released01/14/2000
Lead Analyst(s)
  • Jackie Sheridan-Moore

September 15, 1999

Application received.

September 17, 1999

Formal request accepted for review.

January 14, 2000

Decision made limiting Medicare's current policy of contractor discretion. See Decision Memorandum dated 1/14/00.

January 27, 2000

Letter sent informing requestor of decision to limit contractor discretion.
32